Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Aspirin in Preventing Colorectal Cancer in Patients with Colorectal Adenoma

Multiple Cancer Types

This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Colon, Rectal
II
Dai, Qi
NCT02965703
VICCGI17105

Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

COLON MAP: Colorectal Molecular Atlas Project

Colon

Colon
N/A
Shrubsole, Martha
VICCGI1905

Preserving Fertility After Colorectal Cancer: The PREFACE Study

Multiple Cancer Types

Colon, Rectal
N/A
Holowatyj, Andreana
NCT05239338
VICCGI2186

Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial

Multiple Cancer Types

This phase II / III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works to identify patients with stage IIA colon cancer who might benefit from additional treatment with chemotherapy after surgery. ctDNA are small pieces of genetic materials (DNA) that are shed by tumors into the blood. Finding ctDNA in the blood means that there are very likely small amounts of cancer remaining after surgery that may not be detectable using other tests, such as medical imaging. Testing for ctDNA levels may help identify patients with colon cancer who benefit from receiving chemotherapy after surgery. It is not yet known whether giving additional treatment with chemotherapy after surgery to patients who test positive for ctDNA and are at low risk for cancer recurrence would extend their time without disease compared to the usual approach (active surveillance).
Colon, Rectal
II/III
Agarwal, Rajiv
NCT04068103
SWOGGI005

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Multiple Cancer Types

This randomized phase 1b / 2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Colon, Rectal
I/II
Eng, Cathy
NCT04660812
VICCGIP2113

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Multiple Cancer Types

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care. The study will last up to approximately 2 years.
Colon, Gastrointestinal, Lung, Miscellaneous, Non Small Cell, Phase I, Rectal
I
Iams, Wade
NCT04956640
VICCTHOP2155

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Multiple Cancer Types

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Breast, Colon, Lung, Melanoma, Non Small Cell, Ovarian, Phase I, Rectal
I
Berlin, Jordan
NCT04244552
VICCPHI2040

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Multiple Cancer Types

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: - has spread to other parts of the body (metastatic); - has a certain type of abnormal gene called "BRAF"; and - has not received prior treatment. Participants in this study will receive one of the following study treatments: - Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. - Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. - Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. The study team will monitor how each participant responds to the study treatment for up to about 3 years.
Colon, Rectal
III
Eng, Cathy
NCT04607421
VICCGI2085

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Multiple Cancer Types

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The primary objective is to identify a recommended dose and schedule for NUC-3373 when combined with these agents.
Colon, Phase I, Rectal
I
Ciombor, Kristen
NCT03428958
VICCGIP1851

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: